Table 4

Characteristics at ICU admission of patients who received remifentanil for 96 hours or more before discontinuation

Characteristic

ICU-acquired infection

n = 153

No ICU-acquired infection

n = 113

P value

Age

61 ± 14

53 ± 16

< 0.001

Male gender

100 (65)

78 (69)

0.620

SAPS II

51 ± 16

47 ± 19

0.035

LOD score

5.5 ± 3.4

5.2 ± 3.3

0.435

McCabe score

0.028

Nonfatal underlying disease

67 (43)

67 (59)

Ultimately fatal underlying disease

69 (45)

40 (35)

Rapidly fatal underlying disease

17 (11)

6 (5)

Glasgow coma score

10 ± 2

11 ± 2

0.651

Admission category

> 0.999

Medical

110 (71)

82 (72)

Surgical

43 (28)

31 (27)

Transfer from other wards

107 (69)

63 (55)

< 0.024*

Comorbidities

COPD

42 (27)

38 (33)

0.342

Chronic heart failure

37 (24)

20 (17)

0.262

Immunosuppression

34 (22)

20 (17)

0.452

Diabetes mellitus

24 (15)

30 (26)

0.043†

Infection

103 (67)

73 (64)

0.740

Prior antibiotic treatment

76 (49)

51 (45)

0.543

Length of prior hospital stay, days (interquartile range)

1 (0 to 2)

1 (0 to 5)

0.737

Data are presented as mean ± standard deviation or number (%), unless otherwise specified.

* Odds ratio = 1.84, 95% confidence interval = 1.11 to 3.06; † Odds ratio = 0.51, 95% confidence interval = 0.28 to 0.94.

COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; LOD = logistic organ dysfunction; SAPS = simplified acute physiology score.

Nseir et al. Critical Care 2009 13:R60   doi:10.1186/cc7788